FR2757178B1 - Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament - Google Patents

Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament

Info

Publication number
FR2757178B1
FR2757178B1 FR9615343A FR9615343A FR2757178B1 FR 2757178 B1 FR2757178 B1 FR 2757178B1 FR 9615343 A FR9615343 A FR 9615343A FR 9615343 A FR9615343 A FR 9615343A FR 2757178 B1 FR2757178 B1 FR 2757178B1
Authority
FR
France
Prior art keywords
medicament
dna polymerase
vector expressing
expressing dna
polymerase beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9615343A
Other languages
English (en)
Other versions
FR2757178A1 (fr
Inventor
Christophe Cazaux
Jean Gerard Tiraby
Pascal Fons
Jean Sebastien Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9615343A priority Critical patent/FR2757178B1/fr
Priority to US09/319,265 priority patent/US6475996B1/en
Priority to EP97951311A priority patent/EP0944724A1/fr
Priority to JP52631298A priority patent/JP2001512962A/ja
Priority to PCT/FR1997/002274 priority patent/WO1998026077A1/fr
Publication of FR2757178A1 publication Critical patent/FR2757178A1/fr
Application granted granted Critical
Publication of FR2757178B1 publication Critical patent/FR2757178B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9615343A 1996-12-13 1996-12-13 Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament Expired - Fee Related FR2757178B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR9615343A FR2757178B1 (fr) 1996-12-13 1996-12-13 Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament
US09/319,265 US6475996B1 (en) 1996-12-13 1997-12-11 Use of a vector expressing DNA polymerase β as medicine
EP97951311A EP0944724A1 (fr) 1996-12-13 1997-12-11 Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament
JP52631298A JP2001512962A (ja) 1996-12-13 1997-12-11 ＤＮＡポリメラーゼβを発現するベクターの医薬品としての使用
PCT/FR1997/002274 WO1998026077A1 (fr) 1996-12-13 1997-12-11 UTILISATION D'UN VECTEUR EXPRIMANT L'ADN POLYMERASE β COMME MEDICAMENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615343A FR2757178B1 (fr) 1996-12-13 1996-12-13 Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament

Publications (2)

Publication Number Publication Date
FR2757178A1 FR2757178A1 (fr) 1998-06-19
FR2757178B1 true FR2757178B1 (fr) 1999-03-05

Family

ID=9498646

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9615343A Expired - Fee Related FR2757178B1 (fr) 1996-12-13 1996-12-13 Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament

Country Status (5)

Country Link
US (1) US6475996B1 (fr)
EP (1) EP0944724A1 (fr)
JP (1) JP2001512962A (fr)
FR (1) FR2757178B1 (fr)
WO (1) WO1998026077A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816319B1 (fr) * 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
US20090291440A1 (en) * 2006-05-24 2009-11-26 Ken Hirano Method for synthesizing nucleic acid using dna polymerase beta and single molecule sequencing method
WO2009138094A1 (fr) * 2008-05-14 2009-11-19 Sherif Salah Abdul Aziz Compositions pharmaceutiques
CN106061511A (zh) * 2013-12-31 2016-10-26 R1 B3控股公司 用于增强的基因表达的构建体和序列

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0815429B2 (ja) * 1986-12-03 1996-02-21 愛知県 ＤＮＡポリメラーゼβ遺伝子、該遺伝子を有する組換え体プラスミド及び該プラスミドにより形質転換された形質転換体
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5614365A (en) * 1994-10-17 1997-03-25 President & Fellow Of Harvard College DNA polymerase having modified nucleotide binding site for DNA sequencing
EP0802801A2 (fr) * 1994-12-30 1997-10-29 Chiron Corporation Procedes et compostions de traitement de tumeurs solides in vivo

Also Published As

Publication number Publication date
EP0944724A1 (fr) 1999-09-29
FR2757178A1 (fr) 1998-06-19
US6475996B1 (en) 2002-11-05
WO1998026077A1 (fr) 1998-06-18
JP2001512962A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
ATE309366T1 (de) Synthetische hiv-gene
MA22905A1 (fr) Nouvelles sequences d'adn .
EP0937099A4 (fr) Oligomeres inhibant l'expression de genes de l'interleukine
DE69822614D1 (de) Dna kapillare
NO960408D0 (no) DNA sekvenseringsenzymer
EP0870832A4 (fr) Nouvelle adn polymerase
GB9706381D0 (en) Improvements relating to the specificity of gene expression
IL130886A0 (en) Nucleic acid sequencing
EP0939130A4 (fr) Arn polymerase
FR2757178B1 (fr) Utilisation d'un vecteur exprimant l'adn polymerase beta comme medicament
HUP0004577A3 (en) Novel class of nucleic acid cationic transfecting agents
FR2756734B1 (fr) Utilisation de paracetamol comme agent depigmentant
EP0885238A4 (fr) Imitateurs d'acides nucleiques substitues
FR2719306B1 (fr) Utilisation d'un catalyseur en déshydroisomérisation de N-paraffines C4-C5.
FR2746015B1 (fr) Utilisation de l'octopirox comme agent depigmentant
FR2762526B1 (fr) Malaxeur d'alginate ameliore
GB9719359D0 (en) The Use of DNA Sequences
FR2710061B1 (fr) Acides et chlorures d'acides 1,2,3, 4-tétrahydroquinoléine-8-sulfoniques, et leur utilisation comme intermédiaires de synthèse.
EP0801526A4 (fr) Systeme de transduction de genes
DE69730411D1 (de) Metastasen induzierende dna's
FR2767328B1 (fr) Utilisation de produits polyhydroxyles pour la preparation de polyisocyanates polyfonctionnels
FR2732339B1 (fr) Nouveaux agents de clivage d'adn a photo-induction
FR2744016B1 (fr) Utilisation d'extrait d'algue macroscopique comme transporteur d'oxygene
FR2774698B1 (fr) Utilisation d'elements de regulation negative pour l'expression neurospecifique de transgenes

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070831